Lupus Nephritis

Introduction
 

Lupus nephritis (LN) is one of the most severe organ manifestations of systemic lupus erythematosus (SLE), an autoimmune disease characterised by loss of self-tolerance and proliferation of autoantibodies.1,2 LN is characterised by the formation and deposition of immune complexes that lead to inflammation and fibrosis within the glomeruli and tubulointerstitium of the kidneys.3,4 Flares of disease activity result in progressive nephron loss reflected in a declining glomerular filtration rate (see Figure 1)5 and substantially increased risk of end-stage kidney disease (ESKD) and death.3,6

Nephrology Hub, Kidney Disease ,Lupus Nephritis, Risk of kidney disease for patients with LN over a lifetime.Figure 1: Risk of kidney disease for patients with LN over a lifetime.

 

Prevalence


The prevalence of SLE varies by geographic region, and it has been reported to affect more than 3.4 million people worldwide.1,7 With approximately 50% of patients with SLE developing LN,3,5,8 the estimated number of people living with LN amounts to 1.4 million.1 Approximately 90% of people living with SLE are women.1 The prevalence of LN in SLE patients is greater in African American (34–51%), Hispanic (31–49%), and Asian (33–82%) individuals than in Caucasians (14–23%).5
 

Disease Burden


LN is associated with mortality rates that are 6 times higher than those of the general population.6

Approximately 50% of SLE patients will develop LN within 5 years of SLE diagnosis,3,5,8 and up to 30% of patients with LN will develop ESKD within 10 years of diagnosis, requiring kidney replacement therapy (dialysis or transplantation), despite treatment with current available therapies.3,8,9 Overall, 7-31% of patients have LN at SLE diagnosis;10 whilst women of childbearing age are most predominantly affected by SLE, men with SLE are at a greater risk of developing LN.3
 

Unmet Medical Need


Currently, there is no cure for LN, and management of the disease relies on controlling inflammation, suppressing the immune system, and the use of other supportive management.11-13 In addition to lifestyle modifications, drug treatments can include antihypertensives, steroids, antimalarials, immunosuppressants, and biologic therapies.11-13 With current treatments, only approximately 30% of patients achieve a clinical response; relapses are common, and concerns about drug-related toxicity persist.5,14

Current guidelines are a valuable source of peer-reviewed information on the management and treatment of patients with LN.11-13
 

Patients’ Needs


Figure 2 depicts patient-perceived benefits for people living with LN as well as the societal impact of the disease.15-20

Nephrology Hub, Kidney Disease, Lupus Nephritis, Systemic Lupus Erythematosus, Patient benefits and societal impact of SLE and LNFigure 2: Patient benefits and societal impact of SLE and LN.15-20

 


Peers’ Perspectives

 

On B-cell depletion


 Prof. Brad Rovin

On the need to act with urgency


 Dr. Ioannis Parodis

On steroids


 Prof. Brad Rovin

On steroids


 Prof. Liz Lightstone

On B-cell depletion


 Dr. Juan Mejia-Vilet

On biopsies


Prof. Brad Rovin and
Dr. Juan Mejia-Vilet

On biomarkers


Prof. Brad Rovin and
Dr. Juan Mejia-Vilet

References

  1. Tsokos G, et al. Nat Rev Rheumatol. 2016;12:716–730.
  2. Hoi A, et al. The Lancet 2024;403:2326–38.
  3. Parikh SV, et al. Am J Kidney Dis 2020;76:265–281.
  4. Mohan C, et al. Nat Rev Nephrol 2023;19:491–508.
  5. Anders HJ, et al. Nat Rev Dis Primers. 2020;6:7.
  6. Hocaoglu M, et al. Arthritis Rheumatol 2023;75:567–573.
  7. Tian J, et al. Ann Rheum Dis 2023:82:351–56.
  8. Bechler KK, et al. AMIA Annu Symp Proc. 2023;2022:221–230.
  9. Mok CC, et al. Nat Rev Rheumatol 2023;19:227–238.
  10. Mahajan A, et al. Lupus 2020;29:1011–1020.
  11. Kidney Disease: Improving Global Outcomes Lupus Nephritis Work Group, KDIGO 2024 Clinical Practice Guideline for glomerulonephritis. Kidney Int Supplements 2012, 2, 221–232.
  12. Kidney Disease: Improving Global Outcomes (KDIGO) Lupus Nephritis Work Group. Kidney Int. 2024;105:S1–S69.
  13. Fanouriakis A, et al. Ann Rheum Dis. 2024;83:15–29.
  14. Parodis I, et al. Autoimmun Rev 2024;23:103418.
  15. Lupus and Allied Diseases Association, Inc, Lupus Foundation of America, and Lupus Research Alliance. Lupus: Patient Voices Report on Externally-led Patient-Focused Drug Development Meeting. 2018. https://s3.amazonaws.com/stg.files.lupus.org/public/images/Advocacy/Documents/Lupus%20-%20Patient%20Voices%20Report.pdf. Accessed August 2024.
  16. Lupus Europe. Patient Panel 2 project report. 2016. https://www.lupus-europe.org/wp-content/uploads/2018/10/patient-panel-II-report-Short-final.pdf. Accessed August 2024.
  17. Lupus Europe. Patient Panel 3 project report. 2018. https://www.lupus-europe.org/wp-content/uploads/2018/10/patient-panel-III-report-Final.pdf. Accessed August 2024.
  18. Lupus Europe. Lupus Europe Convention 2023 report. 2023. https://www.lupus-europe.org/wp-content/uploads/2023/07/Convention-Report-2023.pdf.  Accessed August 2024.
  19. Cornet A, et al. Lupus Sci Med. 2021;8:e000469.
  20. Roche, Data on file.

Welcome to Medically

The Roche Science Hub

This website is a non-promotional global resource intended to facilitate transparent scientific exchange regarding developments in medical research, diagnostics, and disease management. It is intended for healthcare professionals.

Not a healthcare professional? Browse:

This global website is intended for healthcare professionals outside the UK, US, Canada and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same.

You are Leaving Medically

By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.

You are Leaving the Global Medically Site

By following this link, you are being redirected to another Roche page.